This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (136)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

A Misnomer?

Robert A. Kyle, MD

JAMA. 1984;251(14):1849-1854.

Abstract
A series of 241 patients with monoclonal protein but no evidence of multiple myeloma, macroglobulinemia, amyloidosis, or lymphoma (benign monoclonal gammopathy) were followed up for more than ten years. The patients were classified as follows: group 1, patients without increase of monoclonal serum protein during follow-up (benign) (37%); group 2, patients with greater than 50% increase of monoclonal protein or development of monoclonal urine protein (5%); group 3, patients who died of unrelated causes (39%); and group 4, patients in whom myeloma, macroglobulinemia, amyloidosis, or related diseases developed (19%). The median interval from recognition of the monoclonal protein to diagnosis of multiple myeloma was 98 months; macroglobulinemia, 115 months; and systemic amyloidosis, 92 months. No laboratory or clinical data initially differentiated patients with benign gammopathy from those in whom serious diseases developed. Consequently, serial measurement of serum monoclonal protein is essential.

(JAMA 1984;251:1849-1854)

Author Affiliations
From the Division of Hematology and Internal Medicine, Mayo Clinic and Mayo Foundation, Rochester, Minn.

Footnotes
Reprint requests to Mayo Clinic, 200 First St SW, Rochester, MN 55905 (Dr Kyle).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma
Dispenzieri et al.
Blood 2008;111:785-789.
ABSTRACT | FULL TEXT  

Monoclonal Gammopathy of Undetermined Significance
Blade
NEJM 2006;355:2765-2770.
FULL TEXT  

On the "Significance" of Monoclonal Gammopathy of Undetermined Significance
Blade
Mayo Clin Proc. 2004;79:855-856.
 

Long-term Follow-up of 241 Patients With Monoclonal Gammopathy of Undetermined Significance: The Original Mayo Clinic Series 25 Years Later
Kyle et al.
Mayo Clin Proc. 2004;79:859-866.
ABSTRACT  

DNA Methylation Profiles of Lymphoid and Hematopoietic Malignancies
Takahashi et al.
Clin. Cancer Res. 2004;10:2928-2935.
ABSTRACT | FULL TEXT  

Prognostic Factors for Malignant Transformation in Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma
Cesana et al.
JCO 2002;20:1625-1634.
ABSTRACT | FULL TEXT  

Chronic Cryptogenic Sensory Polyneuropathy: Clinical and Laboratory Characteristics
Wolfe et al.
Arch Neurol 1999;56:540-547.
ABSTRACT | FULL TEXT  

Computed Tomography in Diagnosis and Management of Multiple Myeloma and Its Variants
Kyle et al.
Arch Intern Med 1985;145:1451-1452.
ABSTRACT  

IgM Gammopathy and the Lupus Anticoagulant Syndrome in Habitual Aborters
Gleicher and Friberg
JAMA 1985;253:3278-3281.
ABSTRACT